For the use only of Registered Medical Practitioners or a Hospital or a Laboratory

BETNOVATE - N

1. GENERIC NAME

Betamethasone Valerate and Neomycin Skin Cream

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Contains:
Betamethasone Valerate IP equivalent to Betamethasone 0.10 % w/w
Neomycin Sulphate IP 0.5% w/w
Chlorocresol IP 0.1% w/w
(as preservative) in a non-greasy base

List of Excipients

Chlorocresol (as preservative)

Cetomacrogol 1000
Cetostearyl alcohol
White soft paraffin
Liquid paraffin
Sodium dihydrogen phosphate dihydrate
Phosphoric acid or sodium hydroxide (for pH adjustment)
Purified water

For important information about some of these excipients see 4.4 Special Warnings and
Precautions for Use.

3. DOSAGE FORM AND STRENGTH

Cream

For information on strength(s) refer 2. Qualitative and Quantitative Composition above.

4. CLINICAL PARTICULARS

4.1 Therapeutic Indication

Betamethasone valerate is a potent topical corticosteroid indicated for the relief of the
inflammatory and pruritic manifestations of steroid responsive dermatoses. Neomycin sulphate
is an aminoglycoside broad spectrum antibiotic.

1
Topical preparations combining betamethasone valerate and neomycin sulphate are indicated
for the treatment of the following conditions where secondary bacterial infection is present,
suspected, or likely to occur:

• Atopic dermatitis
• Nummular dermatitis (discoid eczema)
• Prurigo nodularis
• Psoriasis (excluding widespread plaque psoriasis)
• Lichen simplex chronicus (neurodermatitis) and lichen planus
• Seborrhoeic dermatitis
• Irritant or allergic contact dermatitis
• Insect bite reactions
• Miliaria (prickly heat)
• Anal and genital intertrigo
• Otitis externa (see 4.3 Contraindications).

4.2 Posology and Method of Administration

Creams are especially appropriate for moist or weeping surfaces.

Adults and adolescents

Apply thinly and gently rub in using enough to cover the entire affected area once or twice
daily for up to seven days, then change to another corticosteroid preparation not containing
neomycin sulphate if further treatment is required. Allow adequate time for absorption after
each application before applying an emollient.

In the more resistant lesions, such as the thickened plaques of psoriasis on elbows and knees,
the effect of BETNOVATE-N can be enhanced, if necessary, by occluding the treatment area
with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory
response in such lesions, thereafter improvement can usually be maintained by regular
application without occlusion.

Treatment should not be continued for more than seven days without medical supervision. If
the condition worsens or does not improve within seven days, treatment and diagnosis should
be re-evaluated.

Children aged 2 years and over

BETNOVATE-N is suitable for use in children (2 years and over) at the same dose as adults. A
possibility of increased absorption exists in very young children, thus BETNOVATE-N is
contraindicated in neonates and infants (less than 2 years) (see 4.3 Contraindications).

Children are more likely to develop local and systemic side effects of topical corticosteroids
and, in general, require shorter courses and less potent agents than adults.

Care should be taken when using BETNOVATE-N to ensure the amount applied is the minimum
that provides therapeutic benefit.

2
Elderly

BETNOVATE-N is suitable for use in the elderly. Clinical studies have not identified difference
in responses between the elderly and younger patients. The greater frequency of decreased
hepatic or renal function in the elderly may delay elimination if systemic absorption occurs.
Therefore, the minimum quantity should be used for the shortest duration to achieve the desired
clinical benefit.

Renal Impairment

Dosage should be reduced in patients with reduced renal function (see 4.4 Special Warnings
and Precautions for Use).

4.3 Contraindications

BETNOVATE-N is contraindicated in children under 2 years of age.

Due to the known ototoxic and nephrotoxic potential of neomycin sulphate, the use of
BETNOVATE-N in large quantities or on large areas for prolonged periods of time is
contraindicated in circumstances where significant systemic absorption may occur (see 4.2
Posology and Method of Administration).

The following conditions should not be treated with BETNOVATE-N:

• Rosacea
• Acne vulgaris
• Perioral dermatitis
• Pruritus without inflammation
• Perianal and genital pruritus
• Primary cutaneous viral infections
• Primary infected skin lesions caused by infection with fungi, or bacteria
• Primary or secondary infections due to yeasts
• Secondary infections due to Pseudomonas or Proteus species
• Otitis externa when the ear drum is perforated, because of the risk of ototoxicity

4.4 Special Warnings and Precautions for Use

Hypersensitivity

BETNOVATE - N should be used with caution in patients with a history of local hypersensitivity
to betamethasone, neomycin or to any of the excipients in the preparation. Local
hypersensitivity reactions (see 4.8 Undesirable Effects) may resemble symptoms of the
condition under treatment.

Pseudomembranous colitis

Pseudomembranous colitis has been reported with the use of antibiotics and may range in
severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in

3
patients who develop diarrhoea during or after antibiotic use. Although this is less likely to
occur with topically applied BETNOVATE-N. If prolonged or significant diarrhoea occurs or
the patient experiences abdominal cramps, treatment should be discontinued immediately and
the patient investigated further.

Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression

Manifestations of hypercortisolism (Cushing’s syndrome) and reversible hypothalamic-

pituitary-adrenal (HPA) axis suppression can occur in some individuals as a result of increased
systemic absorption of topical corticosteroids. If either of the above are observed, withdraw the
drug gradually by reducing the frequency of application, or by substituting a less potent
corticosteroid. Abrupt withdrawal of treatment may result in glucocorticosteroid insufficiency
(see 4.8 Undesirable Effects).

Risk factors for increased corticosteroidal systemic effects are:

• Potency and formulation of topical corticosteroid

• Duration of exposure
• Application to a large surface area
• Use on occluded areas of skin e.g. on intertriginous areas or under occlusive dressings
(nappies may act as an occlusive dressing)
• Increasing hydration of the stratum corneum
• Use on thin skin areas such as the face
• Use on broken skin or other conditions where the skin barrier may be impaired.

Visual disturbances

Visual disturbance has been reported by patients using systemic and / or topical corticosteroids.
If a patient has blurred vision or other visual disturbances, consider evaluation of possible
causes which may include cataract, glaucoma or central serous chorioretinopathy.

Use in children

In comparison with adults, children may absorb proportionally larger amounts of topical
corticosteroids and thus be more susceptible to systemic adverse effects. This is because
children have an immature skin barrier and a greater surface area to body weight ratio compared
with adults.

In children under 12 years of age, long term continuous topical corticosteroid therapy should
be avoided where possible, as adrenal suppression can occur.

Use in psoriasis

Topical corticosteroids should be used with caution in psoriasis as rebound relapses,

development of tolerance, risk of generalised pustular psoriasis and development of local or
systemic toxicity due to impaired barrier function of the skin have been reported in some cases
(see 4.8 Undesirable Effects). If used in psoriasis careful patient supervision is important.

4
Dilution

Products which contain antimicrobial agents should not be diluted.

Contact sensitisation

Extended or recurrent application of BETNOVATE-N may increase the risk of contact

sensitisation.

Ototoxicity and nephrotoxicity

Following significant systemic absorption, aminoglycosides such as neomycin can cause

irreversible ototoxicity. Neomycin also has nephrotoxic potential (see 4.3 Contraindications).

Renal impairment

In renal impairment the plasma clearance of neomycin is reduced (see 4.2 Posology and
Method of Administration).

Application to the face

Prolonged application to the face is undesirable as this area is more susceptible to atrophic
changes.

Application to the eyelids

If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye, as
cataract and glaucoma might result from repeated exposure.

Infection

Extension of infection may occur due to the masking effect of the steroid. Any spread of
infection requires withdrawal of topical corticosteroid therapy and administration of
appropriate systemic antimicrobial therapy.

Infection risk with occlusion

Bacterial infection is encouraged by the warm, moist conditions within skin folds or caused by
occlusive dressings. When using occlusive dressings, the skin should be cleansed before a fresh
dressing is applied.

Chronic leg ulcers

Topical corticosteroids are sometimes used to treat the dermatitis around chronic leg ulcers.
However, this use may be associated with a higher occurrence of local hypersensitivity
reactions and an increased risk of local infection.

5
Flammability risk

BETNOVATE-N cream contain paraffin. Instruct patients not to smoke or go near naked flames
due to the risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact
with this product burns more easily and is a serious fire hazard. Washing clothing and bedding
may reduce product build-up but not totally remove it.

4.5 Drug Interactions

Co-administered drugs that can inhibit CYP3A4 (e.g. ritonavir, itraconazole) have been shown
to inhibit the metabolism of corticosteroids leading to increased systemic exposure. The extent
to which this interaction is clinically relevant depends on the dose and route of administration
of the corticosteroids and the potency of the CYP3A4 inhibitor.

Following significant systemic absorption, neomycin sulphate can intensify and prolong the
respiratory depressant effects of neuromuscular blocking agents.

Possibility of cumulative toxicity should be considered when neomycin sulphate is applied

topically in combination with systemic aminoglycoside therapy.

4.6 Use in Special Populations

Fertility

There are no data in humans to evaluate the effect of BETNOVATE-N on fertility.

Pregnancy

There are limited data from the use of BETNOVATE-N in pregnant women.

Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal

development (see 6. Nonclinical Properties). The relevance of this finding to humans has not
been established.

However, neomycin present in maternal blood can cross the placenta and may give rise to a
theoretical risk of foetal toxicity (see 6. Nonclinical Properties). Thus, use of BETNOVATE-N
is not recommended in pregnancy.

Lactation

The safe use of BETNOVATE-N during lactation has not been established.

It is not known whether topical administration of corticosteroids could result in sufficient

systemic absorption to produce detectable amounts in breast milk. Thus, use of BETNOVATE-
N is not recommended in lactation.

6
4.7 Effects on Ability to Drive and Use Machines

There have been no studies to investigate the effect of BETNOVATE-N on driving performance
or the ability to operate machinery. A detrimental effect on such activities would not be
anticipated from the adverse reaction profile of topical BETNOVATE-N.

4.8 Undesirable Effects

Clinical Trial and Post-marketing Data

Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by
frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10),
uncommon (≥1/1,000 and <1/100), rare (≥1/10,000 and <1/1,000) and very rare (<1/10,000),
including isolated reports.

Infections and Infestations

Very rare Opportunistic infection

Immune System Disorders

Very rare Local hypersensitivity

Endocrine Disorders

Very rare Hypothalamic-pituitary adrenal (HPA) axis suppression: (see

also Skin and Subcutaneous Tissue Disorders) Cushingoid
features (e.g. moon face, central obesity), delayed weight
gain/growth retardation in children, osteoporosis, glaucoma,
hyperglycaemia/glucosuria, cataract, hypertension, increased
weight/obesity, decreased endogenous cortisol levels

Skin and Subcutaneous Tissue Disorders

Common Pruritus, local skin burning/pain of skin

Very rare Allergic contact dermatitis/dermatitis, erythema, rash, urticaria,

pustular psoriasis (see 4.4 Special Warnings and Precautions for
Use), skin thinning* / skin atrophy*, skin wrinkling*, skin
dryness*, striae*, telangiectasias*, pigmentation changes*,
hypertrichosis, exacerbation of underlying symptoms, alopecia*,
trichorrhexis*

General Disorders and Administration Site Conditions

Very rare Application site irritation/pain

*Skin features of hypothalamic-pituitary-adrenal (HPA) axis suppression.

7
4.9 Overdose

Symptoms and signs

Topically applied BETNOVATE-N may be absorbed in sufficient amounts to produce systemic

effects. Acute overdosage is very unlikely to occur, however, in the case of chronic overdosage
or misuse, the features of hypercortisolism may occur (see 4.8 Undesirable Effects).

Treatment

In the event of chronic overdose or misuse, topical corticosteroids should be withdrawn

gradually by reducing the frequency of application, or by substituting a less potent
corticosteroid, because of the risk of glucocorticosteroid insufficiency.

Consideration should also be given to significant systemic absorption of neomycin sulphate

(see 4.4 Special Warnings and Precautions for Use). If this is suspected, use of the product
should be stopped and the patient's general status, hearing acuity, renal and neuromuscular
functions should be monitored. Blood levels of neomycin sulphate should also be determined.
Haemodialysis may reduce the serum level of neomycin sulphate.

Further management should be as clinically indicated or as recommended by the National

Poisons Centre, where available.

5. PHARMACOLOGICAL PROPERTIES

5.1 Mechanism of Action

Betamethasone valerate

Topical corticosteroids act as anti-inflammatory agents via multiple mechanisms to inhibit late
phase allergic reactions including decreasing the density of mast cells, decreasing chemotaxis
and activation of eosinophils, decreasing cytokine production by lymphocytes, monocytes,
mast cells and eosinophils, and inhibiting the metabolism of arachidonic acid.

Neomycin sulphate

Neomycin interferes with bacterial protein synthesis by binding to 30S ribosomal subunits.

5.2 Pharmacodynamic Properties

ATC code

D07CC01 Corticosteroids, potent, combinations with antibiotics - Betamethasone and

antibiotics

Betamethasone valerate

Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties.

8
Neomycin sulphate

Neomycin has a bactericidal action against many Gram-negative bacteria but it lacks activity
against Pseudomonas aeruginosa. It has partial activity against Gram-positive bacteria. It is
used topically in the treatment of infections of the skin, ear, and eye due to susceptible
staphylococci and other organisms.

5.3 Pharmacokinetic Properties

Absorption

Betamethasone valerate

Topical corticosteroids can be systemically absorbed from intact healthy skin. The extent of
percutaneous absorption of topical corticosteroids is determined by many factors, including the
vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease
processes in the skin may also increase percutaneous absorption.

The use of pharmacodynamic endpoints for assessing the systemic exposure of topical
corticosteroids is necessary due to the fact that circulating levels are well below the level of
detection.

Neomycin sulphate

Absorption of neomycin has been reported to occur from wounds and inflamed skin. It is poorly
absorbed from the gastrointestinal tract when administered orally.

Distribution

Neomycin sulphate

Absorbed neomycin distributes to tissues and concentrates in the renal cortex.

Metabolism

Betamethasone valerate

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic
pathways similar to systemically administered corticosteroids. They are metabolised, primarily
in the liver.

Elimination

Betamethasone valerate

Topical corticosteroids are excreted by the kidneys. In addition, some corticosteroids and their
metabolites are also excreted in the bile.

9
Neomycin sulphate

Absorbed neomycin is rapidly excreted by the kidneys as parent compound. It has been
reported to have a half-life of 2 to 3 hours.

6. NONCLINICAL PROPERTIES

6.1 Animal Toxicology or Pharmacology

Non-clinical studies have not been conducted with BETNOVATE-N.

Betamethasone valerate and neomycin sulphate individually have been evaluated in animal
toxicity tests, and the following statements reflect the information available on the individual
components

Genotoxicity

Neomycin was negative in the Ames test, HGPRT mutation assay in Chinese hamster ovary
(CHO) cells and mouse bone marrow micronucleus test.

Pregnancy

Subcutaneous administration of betamethasone 17-valerate to mice or rats at doses ≥ 0.1

mg/kg/day or rabbits at doses ≥ 12 micrograms/kg/day during pregnancy produced foetal
abnormalities including cleft palate and intrauterine growth retardation.

7. DESCRIPTION

Cream

Contains:
Betamethasone Valerate IP equivalent to Betamethasone 0.10 % w/w
Neomycin Sulphate IP 0.5% w/w
Chlorocresol IP 0.1% w/w
(as preservative) in a non-greasy base

List of Excipients

Chlorocresol (as preservative)

Cetomacrogol 1000
Cetostearyl alcohol
White soft paraffin
Liquid paraffin
Sodium dihydrogen phosphate dihydrate
Phosphoric acid or sodium hydroxide (for pH adjustment)
Purified water

For important information about some of these excipients see 4.4 Special Warnings and
Precautions for Use.

10
8. PHARMACEUTICAL PARTICULARS

8.1 Incompatibilities

No incompatibilities have been identified.

8.2 Shelf Life

The expiry date is indicated on the label and packaging.

8.3 Packaging Information

Aluminium collapsible tube or Lamitube in a carton.

8.4 Storage and Handling Instructions

Store at a temperature not exceeding 25°C.

Do not freeze.

Keep out of reach of children.

Do not dilute.

9. PATIENT COUNSELLING INFORMATION

Registered Medical Practitioners may counsel their patients (and/or patients’ caregiver as
applicable) about the special warnings and precautions for use, drug interactions, undesirable
effects, and any relevant contraindications of BETNOVATE-N. Patients (and/or patients'
caregiver) may also be informed about posology, method of administration and
storage/handling information as applicable.

10. DETAILS OF MANUFACTURER

The Manufacturing Site details are mentioned on the label and packaging.

For further information please contact:

GlaxoSmithKline Pharmaceuticals Limited.
Registered Office:
Dr. Annie Besant Road, Worli
Mumbai - 400 030.

11. DETAILS OF PERMISSION OR LICENCE NUMBER WITH DATE

Manufacturing Licence number is indicated on the label and packaging.

11
12. DATE OF REVISION

07-FEB-2024

Trademarks are owned by or licensed to the GSK group of companies.

Version: BEVN/PI/IN/2024/01

Adapted from:
Betamethasone 17-valerate-Neomycin sulphate GDS v 12 dated 19 May 2020

12